Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.82 |
| ▸ | THRB | P10828 | 8/20 | 0.75 |
| ▸ | THRA | P10827 | 6/20 | 0.75 |
| ▸ | MEN1 | O00255 | 5/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | PPARG | P37231 | 4/20 | 0.75 |
| ▸ | TTR | P02766 | 2/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.75 |
| ▸ | HTR2B | P41595 | 1/20 | 0.75 |
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diotyrosine SCHEMBL147579 | 1.00 | SIRT5 (0.82) | SIRT5THRBTHRAMEN1KMT2A | |
| Diotyrosine SCHEMBL147578 | 1.00 | SIRT5 (0.82) | SIRT5THRBTHRAMEN1KMT2A | |
| Diotyrosine SCHEMBL31135680 | 0.98 | SIRT5 (0.79) | SIRT5THRBTHRAMEN1KMT2A | |
| Diotyrosine SCHEMBL14484740 | 0.98 | SIRT5 (0.79) | SIRT5THRBTHRAMEN1KMT2A | |
| Diotyrosine SCHEMBL5801627 | 0.98 | SIRT5 (0.79) | SIRT5THRBTHRAMEN1KMT2A | |
| Diotyrosine SCHEMBL1741366 | 0.98 | SIRT5 (0.79) | SIRT5THRBTHRAMEN1KMT2A | |
| Diotyrosine SCHEMBL31135662 | 0.98 | SIRT5 (0.79) | SIRT5THRBTHRAMEN1KMT2A | |
| Diotyrosine SCHEMBL28737936 | 0.98 | SIRT5 (0.79) | SIRT5THRBTHRAMEN1KMT2A | |
| Diotyrosine SCHEMBL16416106 | 0.98 | SIRT5 (0.79) | SIRT5THRBTHRAMEN1KMT2A | |
| Diotyrosine SCHEMBL28737934 | 0.98 | SIRT5 (0.79) | SIRT5THRBTHRAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118914574-A | Free triiodothyronine magnetic particle chemiluminescence detection kit and preparation method thereof | 郑州达诺生物技术有限公司 | 2024-11-08 | — | — | CN | claimed |
| EP-1487493-B1 | CONJUGATES OF CYTOTOXIC AGENTS AND BIOLOGICALLY ACTIVE PEPTIDES | UNIV TULANE (US) | 2010-01-20 | — | — | EP | claimed |
| EP-1131343-A4 | HYDROPHILIC SOMATOSTATIN ANALOGS | ADMINISTRATORS OFTHE TULANE UN (US) | 2005-02-02 | — | — | EP | claimed |
| US-6465613-B1 | ADMINISTERING A SOMATOSTATIN DERIVATIVE TO A PATIENT FOR SELECTIVELY TARGETING AND ARRESTING THE GROWTH OF AN ANGIOGENIC BLOOD VESSEL OR A CELL | TULANE UNIVERSITY | 2002-10-15 | — | — | US | claimed |
| EP-1131343-A1 | HYDROPHILIC SOMATOSTATIN ANALOGS | THE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND (US) | 2001-09-12 | — | — | EP | claimed |
| WO-2000031122-A1 | HYDROPHILIC SOMATOSTATIN ANALOGS | TULANE UNIVERSITY (US) | 2000-06-02 | — | — | WO | claimed |
| EP-4673162-A1 | PATHOGEN-SPECIFIC PEPTIDE TO BLOCK VIRULENCE-RELATED SIGNALING IN CANDIDA ALBICANS | I3S - Instituto de Investigação e Inovação em Saúde, Associação (PT) | 2026-01-07 | — | — | EP | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| WO-2001066147-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2001-09-13 | — | — | WO | disclosed |
| EP-1131343-A1 | HYDROPHILIC SOMATOSTATIN ANALOGS | THE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000031122-A1 | HYDROPHILIC SOMATOSTATIN ANALOGS | TULANE UNIVERSITY (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | SIRT5 4840/4885THRB 2002/4885THRA 1549/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | SIRT5 3400/4885THRB 3982/4885THRA 3752/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | SIRT5 4389/4885THRB 3115/4885THRA 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.